Cover Image
市場調查報告書

孤兒藥市場:各疾病類型(腫瘤,腸胃,肺,神經,血液,心血管,其他),各產品類型,各流通管道-全球產業分析,規模,佔有率,成長,趨勢及2017∼2025年的預測

Orphan Drugs Market (Disease Type - Oncology, Gastrointestinal, Pulmonary, Neurology, Hematology, Cardiovascular, and Others; Product Type; Distribution Channel) - Global Industry Analysis, Size, Share, Volume, Growth, Trends, and Forecast 2017 - 2025

出版商 Transparency Market Research 商品編碼 563617
出版日期 內容資訊 英文 199 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
孤兒藥市場:各疾病類型(腫瘤,腸胃,肺,神經,血液,心血管,其他),各產品類型,各流通管道-全球產業分析,規模,佔有率,成長,趨勢及2017∼2025年的預測 Orphan Drugs Market (Disease Type - Oncology, Gastrointestinal, Pulmonary, Neurology, Hematology, Cardiovascular, and Others; Product Type; Distribution Channel) - Global Industry Analysis, Size, Share, Volume, Growth, Trends, and Forecast 2017 - 2025
出版日期: 2017年09月21日 內容資訊: 英文 199 Pages
簡介

孤兒藥市場,由於罕見疾病的罹患率上升和政府,非政府機關對意識提升的著重,研究開發援助等,今後將大幅成長。

本報告提供全球孤兒藥市場相關調查,市場的各疾病類型,各產品類型,各流通管道,各地區趨勢,及打入市場的主要企業簡介等彙整資料。

第1章 序論

第2章 假設和調查方法

第3章 摘要整理

第4章 市場概要

  • 簡介
  • 概要
  • 市場趨勢
    • 促進要素
    • 阻礙要素
    • 趨勢
  • 市場分析與預測
  • 市場預測
  • 波特五力分析
  • 製造企業
  • SWOT分析
  • 法律規章方案
  • 孤兒藥政策比較分析
  • 罕見疾病罹患率
  • 價格
  • 主要的會議
  • 主要產品
  • 藥物獨佔性
  • 臨床實驗分析

第5章 各疾病類型市場分析與預測

  • 簡介和定義
  • 主要調查結果/發展
  • 市場價值預測
    • 腫瘤
    • 腸胃
    • 神經
    • 血液
    • 心血管
    • 代謝性疾病
    • 內分泌
    • 感染疾病
    • 其他
  • 市場魅力度

第6章 各產品市場分析與預測

  • 簡介和定義
  • 主要調查結果/發展
  • 市場價值預測
    • 生技藥品
    • 非生技藥品
  • 市場魅力度

第7章 各流通管道市場分析與預測

  • 簡介和定義
  • 主要調查結果/發展
  • 市場價值預測
    • 院內藥局
    • 特殊藥局
    • 零售藥局
    • 其他
  • 市場魅力度

第8章 各地區市場規模與預測

  • 主要調查結果
  • 市場價值預測
    • 北美
    • 歐洲
    • 其他
  • 市場魅力度

第9章 北美市場

第10章 歐洲市場

第11章 其他各國

第12章 各國概要

第13章 競爭環境

  • 市場參與企業
  • 企業簡介
    • Novartis AG
    • Bristol-Myers Squibb Company
    • Celgene Corporation
    • F. Hoffmann-La Roche Ltd.
    • Pfizer, Inc.
    • Sanofi S.A.
    • Alexion Pharmaceuticals, Inc.
    • Eli Lilly and Company
    • Novo Nordisk A/S
    • AstraZeneca plc
    • Eisai株式會社
    • 第一三共株式會社
    • Bayer AG
    • GlaxoSmithKline plc
    • Merck & Co., Inc.
    • Johnson & Johnson
    • Biogen, Inc.
    • Shire plc
    • Amgen, Inc.

圖表

目錄

Global Orphan Drugs Market: Overview

Orphan diseases can be defined as the medical conditions which impacts a small group of the population and are mostly genetic in nature. For the treatment of these rare diseases pharmaceutical agents are specifically developed which are known as orphan drugs. The market for these orphan drugs is anticipated to grow significantly in the forecast period, owing to the rising prevalence of rare diseases, focus of government and non-government organizations on creating awareness, research and development grants, and fee waivers and tax credits offered, among others.

Global Orphan Drugs Market: Research Methodology

The research is a combination of primary and secondary research, conducted for understanding and arriving at trends, used to forecast the expected revenue of drugs employed in the treatment of rare diseases in the near future. Primary research formed the bulk of our research efforts with information collected from in-depth interviews and discussions with a number of key industry experts and opinion leaders. Secondary research involved study of company websites, annual reports, press releases, investor presentations, analyst presentation and various international and national databases. The report provides estimated market size in terms of US$ Bn for disease type, product type, distribution channel, and geography for the period 2015 to 2025, considering the macro and micro environmental factors. The revenue generated from each disease type, product type, and distribution channel was calculated by considering the prevalence of rare diseases, orphan drug approvals, regulatory procedures, and the awareness of orphan diseases across all the geographies.

The market report comprises an elaborated executive summary, which includes market snapshot that provides information about various segments of the market. It also provides information and data analysis of the market with respect to market segments based on disease type, product type, distribution channel, and geography. The market overview section of the report analyzes market dynamics such as drivers, restraints and opportunities that influences the nurse call systems market in the current and future scenario. The report also provides Porter's five forces analysis, the acquisitions timeline of orphan drug companies, SWOT analysis of the market, regulatory scenario, comparative analysis of orphan drug policies, rare diseases prevalence, pricing scenario of the orphan drugs, major selling orphan drugs, and drug exclusivity of certain of the orphan drugs, for the market.

Market share analysis among the market players is analyzed to signify the contribution of these players in the market in terms of percentage share. All these factors will help the market players to decide about the business strategies and plans to strengthen their positions in the global market. Based on geography, the market has been analyzed for major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The study also covers detailed country analysis contributing majorly in the nurse call systems market.

Global Orphan Drugs Market: Competitive Landscape

The report also profiles the major players in the market and provides various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Companies profiled in the nurse call systems market report are Novartis AG, Bristol-Myers Squibb Company, Celgene Corporation, F. Hoffmann-La Roche Ltd., Pfizer, Inc., Sanofi S.A., Alexion Pharmaceuticals, Inc., Eli Lilly and Company, Novo Nordisk A/S, AstraZeneca plc, Eisai Co., Ltd., Daiichi Sankyo Company Limited, Bayer AG, GlaxoSmithKline plc, Merck & Co., Inc., Johnson & Johnson, Biogen, Inc., Shire plc, and Amgen, Inc., among others.

The Orphan Drugs Market has been segmented as follows:

  • Orphan Drugs Market, by Disease Type, Revenue (US$ Bn) 2015-2025
  • Oncology
  • Gastrointestinal
  • Pulmonary
  • Neurology
  • Hematology
  • Cardio-vascular
  • Metabolic disorders
  • Endocrinology
  • Infectious diseases
  • Others
  • Orphan Drugs Market, by Product Type, Revenue (US$ Bn) 2015-2025
  • Biologic
  • Non-biologic
  • Orphan Drugs Market, by Distribution Channel, Revenue (US$ Bn) 2015-2025
  • Hospital Pharmacies
  • Speciality Pharmacies
  • Retail pharmacies
  • Others
  • Orphan Drugs Market Revenue, by Geography (US$ Bn), 2015-2025
  • North America
  • U.S.
  • Canada
  • Europe
  • U.K.
  • Germany
  • Spain
  • France
  • Italy
  • Rest of Europe
  • Rest of the World
  • Japan
  • Australia
  • China
  • Brazil
  • South Korea
  • Others

Table of Contents

Section 1 Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

Section 2 Assumptions and Research Methodology

Section 3 Executive Summary

Section 4 Market Overview

  • 4.1. Introduction
    • 4.1.1 Product Type Definition
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
      • 4.3.1.1. Rising prevalence of rare diseases
      • 4.3.1.2. R&D Grants
      • 4.3.1.3. Orphan Drugs provide high return on investments
      • 4.3.1.4. First-mover advantage
      • 4.3.1.5. Focus on awareness programs
      • 4.3.1.6. Tax credits and fee waivers
    • 4.3.2. Restraints
      • 4.3.2.1. High cost of treatment
      • 4.3.2.2. Dearth of trained medical professionals
      • 4.3.2.3. Non-availability of approved drugs worldwide
      • 4.3.2.4. Difficulty in recruiting for clinical trials
    • 4.3.3. Opportunities
      • 4.3.3.1. Unmet clinical needs
      • 4.3.3.2. Strategic mergers and acquisitions
      • 4.3.3.3. Repurposing of drugs
    • 4.3.4. Trends
  • 4.5. Global Orphan Drugs Market Analysis and Forecasts, 2015-2025
  • 4.6. Market Outlook
  • 4.7. Porter's Five Forces Analysis
  • 4.8. Orphan Drug Manufacturing Companies - Acquisitions Timeline
  • 4.9. Orphan Drugs Market- SWOT Analysis
  • 4.10. Regulatory Scenario
  • 4.11. Comparative Analysis of orphan drug policies
  • 4.12. Rare Diseases Prevalence
  • 4.13. Pricing - Orphan Drugs
  • 4.14. Orphan Drugs - Price Volume Analysis
  • 4.15. Major Conferences
  • 4.16. Major selling Orphan drugs
  • 4.17. Orphan Drugs - Drug Exclusivity
  • 4.18. Clinical Trial Analysis

Section 5 Global Orphan Drugs Market Analysis and Forecasts, By Disease Type

  • 5.1. Introduction & Definition
  • 5.2. Key Findings / Developments
  • 5.3. Market Value Forecast By Disease Type, 2015-2025
    • 5.3.1. Oncology
    • 5.3.2. Gastrointestinal
    • 5.3.3. Pulmonary
    • 5.3.4. Neurology
    • 5.3.5. Hematology
    • 5.3.6. Cardiovascular
    • 5.3.7. Metabolic Disorders
    • 5.3.8. Endocrinology
    • 5.3.9. Infectious Diseases
    • 5.3.10. Others
  • 5.4. Market Attractiveness By Disease Type

Section 6 Global Orphan Drugs Market Analysis and Forecasts, By Product Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast By Product Type, 2015-2025
    • 6.3.1. Biologic
    • 6.3.2. Non-biologic
  • 6.4. Market Attractiveness By Product Type

Section 7 Global Orphan Drugs Market Analysis and Forecasts, By Distribution Channel

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast By Distribution Channel, 2015-2025
    • 7.3.1. Hospital Pharmacies
    • 7.3.2. Specialty Pharmacies
    • 7.3.3. Retail Pharmacies
    • 7.3.4. Others
  • 7.4. Market Attractiveness By Distribution Channel

Section 8 Global Orphan Drugs Market Analysis and Forecasts, By Region

  • 8.1. Key Findings
  • 8.2. Market Value Forecast By Region
    • 8.2.1. North America
    • 8.2.2. Europe
    • 8.2.3. Rest of the World
  • 8.3. Market Attractiveness by Region

Section 9 North America Orphan Drugs Market Analysis and Forecast

  • 9.1. Introduction
  • 9.2. Key Findings
  • 9.3. Market Value Forecast By Country, 2015-2025
    • 9.3.1. U.S.
    • 9.3.2. Canada
  • 9.4. Market Value Forecast By Disease Type, 2015-2025
    • 9.4.1. Oncology
    • 9.4.2. Gastrointestinal
    • 9.4.3. Pulmonary
    • 9.4.4. Neurology
    • 9.4.5. Hematology
    • 9.4.6. Cardiovascular
    • 9.4.7. Metabolic Disorders
    • 9.4.8. Endocrinology
    • 9.4.9. Infectious Diseases
    • 9.4.10. Others
  • 9.5. Market Value Forecast By Product Type, 2015-2025
    • 9.5.1. Biologic
    • 9.5.2. Non-biologic
  • 9.6. Market Value Forecast By Distribution Channel, 2015-2025
    • 9.6.1. Hospital Pharmacies
    • 9.6.2. Specialty Pharmacies
    • 9.6.3. Retail Pharmacies
    • 9.6.4. Others
  • 9.7. Market Attractiveness Analysis
    • 9.7.1. By Country
    • 9.7.2. By Disease Type
    • 9.7.3. By Product Type
    • 9.7.4. By Distribution Channel

Section 10 Europe Orphan Drugs Market Analysis and Forecast

  • 10.1. Introduction
  • 10.2. Key Findings
  • 10.3. Market Value Forecast By Country, 2015-2025
    • 10.3.1. U.K.
    • 10.3.2. Germany
    • 10.3.3. France
    • 10.3.4. Italy
    • 10.3.5. Spain
    • 10.3.6. Rest of Europe
  • 10.4. Market Value Forecast By Disease Type, 2015-2025
    • 10.4.1. Oncology
    • 10.4.2. Gastrointestinal
    • 10.4.3. Pulmonary
    • 10.4.4. Neurology
    • 10.4.5. Hematology
    • 10.4.6. Cardiovascular
    • 10.4.7. Metabolic Disorders
    • 10.4.8. Endocrinology
    • 10.4.9. Infectious Diseases
    • 10.4.10. Others
  • 10.5. Market Value Forecast By Product Type, 2015-2025
    • 10.5.1. Biologic
    • 10.5.2. Non-biologic
  • 10.6. Market Value Forecast By Distribution Channel, 2015-2025
    • 10.6.1. Hospital Pharmacies
    • 10.6.2. Specialty Pharmacies
    • 10.6.3. Retail Pharmacies
    • 10.6.4. Others
  • 10.7. Market Attractiveness Analysis
    • 10.7.1. By Country
    • 10.7.2. By Disease Type
    • 10.7.3. By Product Type
    • 10.7.4. By Distribution Channel

Section 11 Rest of the World Orphan Drugs Market Analysis and Forecast

  • 11.1. Introduction
  • 11.2. Key Findings
  • 11.3. Market Value Forecast By Country, 2015-2025
    • 11.3.1. Japan
    • 11.3.2. Australia
    • 11.3.3. China
    • 11.3.4. Brazil
    • 11.3.5. South Korea
    • 11.3.6. Others
  • 11.4. Market Value Forecast By Disease Type, 2015-2025
    • 11.4.1. Oncology
    • 11.4.2. Gastrointestinal
    • 11.4.3. Pulmonary
    • 11.4.4. Neurology
    • 11.4.5. Hematology
    • 11.4.6. Cardiovascular
    • 11.4.7. Metabolic Disorders
    • 11.4.8. Endocrinology
    • 11.4.9. Infectious Diseases
    • 11.4.10. Others
  • 11.5. Market Value Forecast By Product Type, 2015-2025
    • 11.5.1. Biologic
    • 11.5.2. Non-biologic
  • 11.6. Market Value Forecast By Distribution Channel, 2015-2025
    • 11.6.1. Hospital Pharmacies
    • 11.6.2. Specialty Pharmacies
    • 11.6.3. Retail Pharmacies
    • 11.6.4. Others
  • 11.7. Market Attractiveness Analysis
    • 11.7.1. By Country
    • 11.7.2. By Disease Type
    • 11.7.3. By Product Type
    • 11.7.4. By Distribution Channel

Section 12 Country Snippets

Section 13 Competition Landscape

  • 13.1. Market Player - Competition Matrix (By Tier and Size of companies)
  • 13.2. Market Share Analysis By Company, 2016
  • 13.3. Company Profiles (Details - Overview, Financials, Recent Developments, Strategy)
    • 13.3.1. Novartis AG
      • 13.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 13.3.1.2. Business Overview
      • 13.3.1.3. Product Portfolio
      • 13.3.1.4. Financial Overview
      • 13.3.1.5. SWOT Analysis
      • 13.3.1.6. Strategic overview
    • 13.3.2. Bristol-Myers Squibb Company
      • 13.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 13.3.2.2. Business Overview
      • 13.3.2.3. Product Portfolio
      • 13.3.2.4. Financial Overview
      • 13.3.2.5. SWOT Analysis
      • 13.3.2.6. Strategic overview
    • 13.3.3. Celgene Corporation
      • 13.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 13.3.3.2. Business Overview
      • 13.3.3.3. Product Portfolio
      • 13.3.3.4. Financial Overview
      • 13.3.3.5. SWOT Analysis
      • 13.3.3.6. Strategic overview
    • 13.3.4. F. Hoffmann-La Roche Ltd.
      • 13.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 13.3.4.2. Business Overview
      • 13.3.4.3. Product Portfolio
      • 13.3.4.4. Financial Overview
      • 13.3.4.5. SWOT Analysis
      • 13.3.4.6. Strategic overview
    • 13.3.5. Pfizer, Inc.
      • 13.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 13.3.5.2. Business Overview
      • 13.3.5.3. Product Portfolio
      • 13.3.5.4. Financial Overview
      • 13.3.5.5. SWOT Analysis
      • 13.3.5.6. Strategic overview
    • 13.3.6. Sanofi S.A.
      • 13.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 13.3.6.2. Business Overview
      • 13.3.6.3. Product Portfolio
      • 13.3.6.4. Financial Overview
      • 13.3.6.5. SWOT Analysis
      • 13.3.6.6. Strategic overview
    • 13.3.7. Alexion Pharmaceuticals, Inc.
      • 13.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 13.3.7.2. Business Overview
      • 13.3.7.3. Product Portfolio
      • 13.3.7.4. Financial Overview
      • 13.3.7.5. SWOT Analysis
      • 13.3.7.6. Strategic overview
    • 13.3.8. Eli Lilly and Company
      • 13.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 13.3.8.2. Business Overview
      • 13.3.8.3. Product Portfolio
      • 13.3.8.4. Financial Overview
      • 13.3.8.5. SWOT Analysis
      • 13.3.8.6. Strategic overview
    • 13.3.9. Novo Nordisk A/S
      • 13.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 13.3.9.2. Business Overview
      • 13.3.9.3. Product Portfolio
      • 13.3.9.4. Financial Overview
      • 13.3.9.5. SWOT Analysis
      • 13.3.9.6. Strategic overview
    • 13.3.10. AstraZeneca plc
      • 13.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 13.3.10.2. Business Overview
      • 13.3.10.3. Product Portfolio
      • 13.3.10.4. Financial Overview
      • 13.3.10.5. SWOT Analysis
      • 13.3.10.6. Strategic overview
    • 13.3.11. Eisai Co., Ltd.
      • 13.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 13.3.11.2. Business Overview
      • 13.3.11.3. Product Portfolio
      • 13.3.11.4. Financial Overview
      • 13.3.11.5. SWOT Analysis
      • 13.3.11.6. Strategic overview
    • 13.3.12. Daiichi Sankyo Company Limited
      • 13.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 13.3.12.2. Business Overview
      • 13.3.12.3. Product Portfolio
      • 13.3.12.4. Financial Overview
      • 13.3.12.5. SWOT Analysis
      • 13.3.12.6. Strategic overview
    • 13.3.13. Bayer AG
      • 13.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 13.3.13.2. Business Overview
      • 13.3.13.3. Product Portfolio
      • 13.3.13.4. Financial Overview
      • 13.3.13.5. SWOT Analysis
      • 13.3.13.6. Strategic overview
    • 13.3.14. GlaxoSmithKline plc
      • 13.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 13.3.14.2. Business Overview
      • 13.3.14.3. Product Portfolio
      • 13.3.14.4. Financial Overview
      • 13.3.14.5. SWOT Analysis
      • 13.3.14.6. Strategic overview
    • 13.3.15. Merck & Co., Inc.
      • 13.3.15.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 13.3.15.2. Business Overview
      • 13.3.15.3. Product Portfolio
      • 13.3.15.4. Financial Overview
      • 13.3.15.5. SWOT Analysis
      • 13.3.15.6. Strategic overview
    • 13.3.16. Johnson & Johnson
      • 13.3.16.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 13.3.16.2. Business Overview
      • 13.3.16.3. Product Portfolio
      • 13.3.16.4. Financial Overview
      • 13.3.16.5. SWOT Analysis
      • 13.3.16.6. Strategic overview
    • 13.3.17. Biogen, Inc.
      • 13.3.17.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 13.3.17.2. Business Overview
      • 13.3.17.3. Product Portfolio
      • 13.3.17.4. Financial Overview
      • 13.3.17.5. SWOT Analysis
      • 13.3.17.6. Strategic overview
    • 13.3.18. Shire plc
      • 13.3.18.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 13.3.18.2. Business Overview
      • 13.3.18.3. Product Portfolio
      • 13.3.18.4. Financial Overview
      • 13.3.18.5. SWOT Analysis
      • 13.3.18.6. Strategic overview
    • 13.3.19. Amgen, Inc.
      • 13.3.19.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 13.3.19.2. Business Overview
      • 13.3.19.3. Product Portfolio
      • 13.3.19.4. Financial Overview
      • 13.3.19.5. SWOT Analysis
      • 13.3.19.6. Strategic overview

List of Tables

  • Table 01: Comparative Analysis of orphan drug policies
  • Table 02: Top selling orphan drugs of 2016
  • Table 03: Orphan Drugs- Drug Exclusivity Details (of Few Orphan Drugs)
  • Table 04: Pipeline Analysis
  • Table 05: Global Orphan Drugs Market Size (US$ Bn) Forecast, by Disease Type, 2015-2025
  • Table 06: Global Orphan Drugs Market Size (US$ Bn) Forecast, by Product Type, 2015-2025
  • Table 07: Global Orphan Drugs Market Size (US$ Bn) Forecast, by Distribution Channel, 2015-2025
  • Table 08: Global Orphan Drugs Market Size (US$ Bn) Forecast, by Region, 2015-2025
  • Table 09: North America Orphan Drugs Market Size (US$ Bn) Forecast, by Country, 2015-2025
  • Table 10: North America Orphan Drugs Market Size (US$ Bn) Forecast, by Product Type, 2015-2025
  • Table 11: North America Orphan Drugs Market Size (US$ Bn) Forecast, by Disease Type, 2015-2025
  • Table 12: North America Orphan Drugs Market Size (US$ Bn) Forecast, by Distribution Channel, 2015-2025
  • Table 13: Europe Orphan Drug Market Size (US$ Bn) Forecast, by Country, 2015-2025
  • Table 14: Europe Orphan Drug Market Size (US$ Bn) Forecast, by Product Type, 2015-2025
  • Table 15: Europe Orphan Drugs Market Size (US$ Bn) Forecast, by Disease Type, 2015-2025
  • Table 16: Europe Orphan Drugs Market Size (US$ Bn) Forecast, by Distribution Channel, 2015-2025
  • Table 17: Rest of the World Orphan Drugs Market Size (US$ Bn) Forecast, by Country, 2015-2025
  • Table 18: Rest of the World Orphan Drugs Market Size (US$ Bn) Forecast, by Product Type, 2015-2025
  • Table 19: Rest of the World Orphan Drugs Market Size (US$ Bn) Forecast, by Disease Type, 2015-2025
  • Table 20: Rest of the World Orphan Drugs Market Size (US$ Bn) Forecast, by Distribution Channel, 2015-2025

List of Figures

  • Figure 01: Global Orphan Drugs Market Size (US$ Mn) and Y-o-Y Growth (%), and Forecast, 2017-2025
  • Figure 02: Market Value Share By Disease Type (2017)
  • Figure 03: Market Value Share By Product Type (2017)
  • Figure 04: Market Value Share By Distribution Channel (2017)
  • Figure 05: Market Value Share By Region (2017)
  • Figure 06: Porter's Five Force Analysis
  • Figure 07: Orphan Drugs Market- SWOT Analysis
  • Figure 08: Regulatory Approval Process- The U.S.
  • Figure 09: Regulatory Approval Process- Europe
  • Figure 10: Regulatory Approval Process- Japan
  • Figure 11: Prevalence of Orphan (rare) diseases
  • Figure 12: Factors contributing to the orphan drugs pricing decision
  • Figure 13: Pricing of certain orphan drugs (US$ per patient per year)
  • Figure 14: Factors for high prices of orphan drugs
  • Figure 15: Orphan Drugs- Price Volume Analysis
  • Figure 16: Conferences held on Orphan Diseases
  • Figure 17: Global Orphan Drugs Market Value Share Analysis, by Disease Type, 2016 and 2025
  • Figure 18: Global Orphan Drugs Market Revenue (US$ Bn) and Y-o-Y Growth (%) Forecast, by Oncology, 2015-2025
  • Figure 19: Global Orphan Drugs Market Revenue (US$ Bn) and Y-o-Y Growth (%) Forecast, by Gastrointestinal, 2015-2025
  • Figure 20: Global Orphan Drugs Market Revenue (US$ Bn) and Y-o-Y Growth (%) Forecast, by Pulmonary, 2015-2025
  • Figure 21: Global Orphan Drugs Market Revenue (US$ Bn) and Y-o-Y Growth (%) Forecast, by Neurology, 2015-2025
  • Figure 22: Global Orphan Drugs Market Revenue (US$ Bn) and Y-o-Y Growth (%) Forecast, by Hematology, 2015-2025
  • Figure 23: Global Orphan Drugs Market Revenue (US$ Bn) and Y-o-Y Growth (%) Forecast, by Cardiovascular,
  • Figure 24: Global Orphan Drugs Market Revenue (US$ Bn) and Y-o-Y Growth (%) Forecast, by Metabolic Disorders, 2015-2025
  • Figure 25: Global Orphan Drugs Market Revenue (US$ Bn) and Y-o-Y Growth (%) Forecast, by Endocrinology,
  • Figure 26: Global Orphan Drugs Market Revenue (US$ Bn) and Y-o-Y Growth (%) Forecast, by Infectious Diseases, 2015-2025
  • Figure 27: Global Orphan Drugs Market Revenue (US$ Bn) and Y-o-Y Growth (%) Forecast, by Others, 2015-2025
  • Figure 28: Global Orphan Drugs Market Attractiveness, by Disease Type, 2017-2025
  • Figure 29: Global Orphan Drugs Market Value Share Analysis, by Product Type, 2016 and 2025
  • Figure 30: Global Orphan Drugs Market Revenue (US$ Bn), and Y-o-Y Growth (%), by Biologic, 2015-2025
  • Figure 31: Global Orphan Drugs Market Revenue (US$ Bn), and Y-o-Y Growth (%), by Non-biologic, 2015-2025
  • Figure 32: Global Orphan Drugs Market Attractiveness, by Product Type 2017-2025
  • Figure 33: Global Orphan Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2025
  • Figure 34: Global Orphan Drugs Market Revenue (US$ Bn), and Y-o-Y Growth (%) Forecast, by Hospital Pharmacies, 2015-2025
  • Figure 35: Global Orphan Drugs Market Revenue (US$ Bn), and Y-o-Y Growth (%) Forecast, by Specialty Pharmacies, 2015-2025
  • Figure 36: Global Orphan Drugs Market Revenue (US$ Bn), and Y-o-Y Growth (%) Forecast, by Retail Pharmacies,
  • Figure 37: Global Orphan Drugs Market Revenue (US$ Bn), and Y-o-Y Growth (%) Forecast, by Others, 2015-2025
  • Figure 38: Global Orphan Drugs Market Attractiveness, by Distribution Channel, 2017-2025
  • Figure 39: Global Orphan Drugs Market Revenue (US$ Bn) Forecast, 2015-2025
  • Figure 40: Global Orphan Drugs Market Value Share Analysis, by Region, 2016 and 2025
  • Figure 41: Global Orphan Drugs Market Attractiveness, by Region, 2017-2025
  • Figure 42: North America Orphan Drugs Market Size (US$ Bn) and Y-o-Y Growth (%) Forecast, 2015-2025
  • Figure 43: North America Orphan Drugs Market Attractiveness Analysis, by Country, 2017-2025
  • Figure 44: North America Orphan Drugs Market Value Share Analysis, by Country, 2016 and 2025
  • Figure 45: North America Orphan Drugs Market Value Share Analysis, by Product Type, 2016 and 2025
  • Figure 46: North America Orphan Drugs Market Value Share Analysis, by Disease Type, 2016 and 2025
  • Figure 47: North America Orphan Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2025
  • Figure 48: North America Orphan Drugs Market Attractiveness Analysis, by Product Type, 2017-2025
  • Figure 49: North America Orphan Drugs Market Attractiveness Analysis, by Distribution Channel, 2017-2025
  • Figure 50: North America Orphan Drugs Market Attractiveness Analysis, by Disease Type, 2017-2025
  • Figure 51: Europe Orphan Drug Market Size (US$ Bn) Forecast, 2015-2025
  • Figure 52: Europe Market Attractiveness Analysis, by Country, 2017-2025
  • Figure 53: Europe Orphan Drug Market Value Share Analysis, by Country, 2016 and 2025
  • Figure 54: Europe Orphan Drug Market Value Share Analysis, by Product Type, 2016 and 2025
  • Figure 55: Europe Orphan Drug Market Value Share Analysis, by Disease Type, 2016 and 2025
  • Figure 56: Europe Orphan Drug Market Value Share Analysis, by Distribution Channel, 2016 and 2025
  • Figure 57: Europe Orphan Drug Market Attractiveness Analysis, by Product type, 2017-2025
  • Figure 58: Europe Orphan Drug Market Attractiveness Analysis, by Distribution Channel, 2017-2025
  • Figure 59: Europe Orphan Drug Market Attractiveness Analysis, by Disease Type, 2017-2025
  • Figure 60: Rest of the World Orphan Drugs Market Size (US$ Bn) and Y-o-Y Growth (%) Forecast, 2015-2025
  • Figure 61: Rest of the World Market Attractiveness Analysis, by Country, 2017-2025
  • Figure 62: Rest of the World Orphan Drugs Market Value Share Analysis, by Country, 2016 and 2025
  • Figure 63: Rest of the World Orphan Drugs Market Value Share Analysis, by Product Type, 2016 and 2025
  • Figure 64: Rest of the World Orphan Drugs Market Value Share Analysis, by Disease Type, 2016 and 2025
  • Figure 65: Rest of the World Orphan Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2025
  • Figure 66: Rest of the World Orphan Drugs Market Attractiveness Analysis, by Product Type, 2017-2025
  • Figure 67: Rest of the World Orphan Drugs Market Attractiveness Analysis, by Distribution Channel, 2017-2025
  • Figure 68: Rest of the World Orphan Drugs Market Attractiveness Analysis, by Disease Type, 2017-2025
  • Figure 69: Global Orphan Drugs Market Share Analysis, by Company (2016)
  • Figure 70: Novartis AG, Breakdown of Net Sales, by Region, 2016
  • Figure 71: Novartis AG, Revenue (US$ Mn) & Y-o-Y Growth (%), 2013-2016
  • Figure 72: Bristol-Myers Squibb Company, Breakdown of Net Sales, by Region, 2016
  • Figure 73: Bristol-Myers Squibb Company, Revenue (US$ Bn) & Y-o-Y Growth (%), 2013-2016
  • Figure 74: Celgene Corporation, Breakdown of Net Sales, by Region, 2016
  • Figure 75: Celgene Corporation, Revenue (US$ Bn) & Y-o-Y Growth (%), 2013-2016
  • Figure 76: F. Hoffmann-La Roche Ltd., Breakdown of Net Sales (Pharmaceutical Division), by Region, 2016
  • Figure 77: F. Hoffmann-La Roche Ltd., Revenue (US$ Bn) & Y-o-Y Growth (%), 2013-2016
  • Figure 78: Pfizer, Inc., Breakdown of Net Sales, by Region, 2016
  • Figure 79: Pfizer, Inc., Revenue (US$ Bn) & Y-o-Y Growth (%), 2013-2016
  • Figure 80: Sanofi S.A., Breakdown of Net Sales, by Region, 2016
  • Figure 81: Sanofi S.A., Revenue (US$ Bn) & Y-o-Y Growth (%), 2013-2016
  • Figure 82: Alexion pharmaceuticals, Inc., Breakdown of Net Sales, by Region, 2016
  • Figure 83: Alexion pharmaceuticals, Inc., Revenue (US$ Bn) and Y-o-Y Growth (%), 2013-2016
  • Figure 84: Eli Lilly and Company, Breakdown of Net Sales, by Region, 2016
  • Figure 85: Eli Lilly and Company, Revenue (US$ Bn) and Y-o-Y Growth (%), 2013-2016
  • Figure 86: Novo Nordisk A/S, Breakdown of Net Sales, by Region, 2016
  • Figure 87: Novo Nordisk A/S, Revenue (US$ Bn) and Y-o-Y Growth (%), 2013-2016
  • Figure 88: AstraZeneca plc, Breakdown of Net Sales, by Region, 2016
  • Figure 89: AstraZeneca plc, Revenue (US$ Bn) and Y-o-Y Growth (%), 2013-2016
  • Figure 90: Eisai Co., Ltd., Breakdown of Net Sales, by Region, 2016
  • Figure 91: Eisai Co., Ltd., Revenue (US$ Bn) and Y-o-Y Growth (%), 2013-2016
  • Figure 92: Daiichi Sankyo Company Limited, Breakdown of Net Sales, by Region, 2016
  • Figure 93: Daiichi Sankyo Company Limited, Revenue (US$ Bn) and Y-o-Y Growth (%), 2013-2016
  • Figure 94: Bayer AG, Breakdown of Net Sales, by Region
  • Figure 95: Bayer AG, Revenue (US$ Bn) and Y-o-Y Growth (%), 2013-2016
  • Figure 96: GlaxoSmithKline plc, Breakdown of Net Sales, by Region, 2016
  • Figure 97: GlaxoSmithKline plc, Revenue (US$ Bn) and Y-o-Y Growth (%), 2013-2016
  • Figure 98: Merck & Co., Inc., Breakdown of Net Sales, by Region, 2016
  • Figure 99: Merck & Co., Inc., Revenue (US$ Bn) and Y-o-Y Growth (%), 2013-2016
  • Figure 100: Johnson & Johnson, Breakdown of Net Sales, by Region, 2016
  • Figure 101: Revenue (US$ Bn) and Y-o-Y Growth (%), 2013-2016
  • Figure 102: Biogen, Inc., Breakdown of Net Sales, by Region, 2016
  • Figure 103: Biogen, Inc., Revenue (US$ Bn) and Y-o-Y Growth (%), 2013-2016
  • Figure 104: Shire plc, Breakdown of Net Sales, by Region, 2016
  • Figure 105: Shire plc, Revenue (US$ Bn) and Y-o-Y Growth (%), 2013-2016
  • Figure 106: Amgen, Inc., Breakdown of Net Sales, by Region, 2016
  • Figure 107: Amgen, Inc., Revenue (US$ Bn) and Y-o-Y Growth (%), 2013-2016
Back to Top